Updated:
Bayer AG
Bayer AG, led by CEO Bill Anderson since 2023, is a life-science conglomerate spanning pharma, consumer health, and crop science, with over €47B in sales.
Bayer AG
Bayer AG was founded in 1863 as a dye manufacturer in Barmen, Germany, and grew into a global life-science corporation. Bill Anderson became CEO in June 2023, taking charge of a group whose current structure emerged from the 2018 acquisition of Monsanto for $63B (per public record). The firm operates three main divisions: Pharmaceuticals (heart disease, oncology, women's health), Consumer Health (over-the-counter brands like Aspirin and Claritin), and Crop Science (seeds, pesticides, digital farming). Bayer invests roughly €6B annually in R&D (per the firm's 2024 annual report) and pursues M&A in adjacent life-science spaces. Confirmed recent deals include the 2024 acquisition of askBio and a partnership with Recursion Pharmaceuticals on AI-driven drug discovery. Geographically, Bayer sells in over 90 countries, with major hubs in Germany, the US (headquarters in Whippany, New Jersey), and Brazil. Bayer employs approximately 100,000 people worldwide. Its Crop Science division is among the largest in global agribusiness, with leading market share in seeds and crop protection. The firm also holds a significant drug pipeline, with late-stage candidates in cardiovascular and oncology. In May 2024, Bayer appointed Juergen Eckhardt to lead its newly formed health-tech investment arm, Bayer Leaps, a venture unit focused on early-stage life-science startups (per the firm, May 2024). Bayer's structural differentiator is its hybrid identity as both a public pharmaceutical manufacturer and an agricultural giant — a combination rare among life-science companies. The firm's integration of Monsanto post-acquisition has driven ongoing litigation over glyphosate-based herbicides, shaping its risk profile and legal strategy. Succession at the CEO level remains tied to shareholder returns and legal resolution.
General information
Firm type
other
Year founded
1863
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Leverkusen
Corporate office
Leverkusen, Germany
Additional offices
San Francisco, United States
Principals
Bill Anderson
CEO
Wolfgang Nickl
CFO
Sector focus
Frequently asked questions
Who runs investment decisions at Bayer?
Investment decisions are made by Bayer's executive board led by CEO Bill Anderson, with divisional leadership for pharma, consumer health, and crop science. The firm's venture arm, Bayer Leaps, operates under Juergen Eckhardt (per public record). CFO Wolfgang Nickl oversees capital allocation.
How does Bayer source proprietary deal flow?
Bayer sources deals through its in-house R&D pipeline, partnerships with biotech firms like Recursion Pharmaceuticals, and its venture capital unit Bayer Leaps. The company also pursues strategic M&A for pipeline expansion (per public record).
Is Bayer structured as a family office or a corporation?
Bayer is a publicly traded German Aktiengesellschaft (AG), not a family office. It is listed on the Frankfurt Stock Exchange and is not managed by a single family; its largest shareholders are institutional investors (per public record).
Does Bayer participate in fund commitments or only direct investments?
Bayer makes direct investments in R&D and acquisitions, but it also operates a venture arm (Bayer Leaps) that invests in external early-stage startups. The firm does not typically commit to external funds as an LP (per public record).
What investment stages does Bayer typically target?
Bayer focuses on late-stage pharmaceutical R&D (Phase II/III trials) and commercial products, but through Bayer Leaps, it targets early-stage seed and Series A opportunities in health tech and agtech (per public record).
Which sectors does Bayer explicitly avoid?
Bayer does not publicly state explicit avoidance sectors, but its operations are concentrated in life sciences—pharmaceuticals, consumer health, and agriculture—and it generally avoids unrelated industries like financial services or energy (per public record).
How is Bayer related to its venture arm, Bayer Leaps?
Bayer Leaps is the corporate venture capital arm of Bayer AG, operating as a wholly owned subsidiary. It makes equity investments in startups aligned with Bayer's health and agtech strategies (per the firm's 2024 announcement).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: